Research programme: musculoskeletal therapeutics - Ablynx

Drug Profile

Research programme: musculoskeletal therapeutics - Ablynx

Alternative Names: Nanobodies - Ablynx

Latest Information Update: 23 Sep 2009

Price : $50

At a glance

  • Originator Ablynx; Procter & Gamble
  • Developer Ablynx
  • Class
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Musculoskeletal disorders
  • Discontinued Metabolic disorders

Most Recent Events

  • 23 Sep 2009 This programme is still in active development
  • 20 Jan 2009 Procter & Gamble ends its research collaboration with Ablynx
  • 18 Jun 2007 Ablynx has reached a second milestone in the agreement with Procter and Gamble
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top